HOME >> MEDICINE >> NEWS
Premature use of stem cell therapy could put patients at risk

The premature use of stem cell therapy could put many patients at risk of viral or prion diseases unless appropriate safety systems are in place, warn experts in this week's BMJ.

The use of human embryonic stem cells has been hailed as the next major step in the battle against serious degenerative disorders, such as diabetes and Parkinson's disease. But is this just hype, and how much hope should patients invest in this technology? These are some of the issues that will be discussed at a public debate in London next week.

The lessons of premature application of gene therapy, the devastation caused by HIV transmission to people with haemophilia, and the crisis caused by bovine spongiform encephalopathy (BSE) should all be learning opportunities, say the authors.

Expansion of stem cell cultures could allow a single stem cell line to be used for many hundreds, if not thousands of patients, exponentially amplifying the potential risk of disease transmission from a single infected donor.

Change is on the way, however. By April 2006, all laboratories for in vitro fertilisation and laboratories for producing cell lines with therapeutic intent will have to comply with the EU Directive on tissues and cells. This will cover selection of donors, testing, and procurement of the starting material for cell lines, tracking cells from donor to recipient, and reporting of adverse events.

The authors suggest a novel alternative approach whereby the expanded stem cell lines themselves could be tested for a variety of pathogens before they are released. This would provide an additional safety step and provide an alternative in the armamentarium for testing these important donations for transplantation.

The drive to be the first to produce cell lines for therapy without appropriate controls could compromise safety for recipients and could lead this technology into the realms of quackery, say the authors. Such fears are already being realis
'"/>

Contact: Emma Dickinson
edickinson@bmj.com
44-207-383-6529
BMJ-British Medical Journal
19-May-2005


Page: 1 2

Related medicine news :

1. Premature or low birthweight babies at significantly increased risk of hyperactivity disorder
2. Premature baby ventilation trial cleared of causing long-term harm to participants
3. Premature babies and SIDS: Doctors should make special effort to talk to parents About Risk
4. Chemotherapy with bevacizumab increases risk of blood clots in arteries
5. Nonsmall cell lung cancer -- chemotherapy before surgery appears better than surgery alone
6. Stroke in nonvascular atrial fibrillation -- anti-coagulants better than anti-platelet therapy
7. Hormone therapy offers new hope for ovarian cancer patients
8. Borderline personality disorder shows improvements with intensive psychotherapy
9. Trial shows circulating tumor cells predict how prostate cancer patients do with chemotherapy
10. Chemotherapy may enhance the effectiveness of brain tumor vaccines
11. Brain-boosting pill alleviates post-chemotherapy fogginess

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:9/22/2017)... ... September 22, 2017 , ... ... other tick-borne diseases through research, education and awareness, today announced the appointment of ... immunologist and microbiologist, Dr. Sellati has more than 20 years of research experience ...
(Date:9/21/2017)... ... ... 38-Year-Old Plastic Surgeon Gill at Aesthetic Surgery Center is Saluted as Young ... Plastic Surgeon Kiranjeet Gill has been awarded as one of the 15th annual 40-under-40 ... was started in 2003 to salute young achievers in Southwest Florida who have distinguished ...
(Date:9/21/2017)... ... 2017 , ... SABRE is raising awareness about personal safety with a Chicago ... November. , The Chicago, Illinois, based self-defense brand has been waiting for an opportunity ... of taking their personal safety into their own hands. , The ads focus on ...
(Date:9/21/2017)... ... September 21, 2017 , ... ... Management Report**, http://www.fdanews.com/products/54818-promotional-communication      , In the competitive world of drug and ... while staying in compliance with FDA rules. , The FDA has issued two ...
(Date:9/21/2017)... ... September 21, 2017 , ... Demonstrating a consistent and ... departments have been awarded five-year accreditation status through the Public Health Accreditation ... served by a PHAB-accredited health department now extend to more than 203 ...
Breaking Medicine News(10 mins):
(Date:9/7/2017)... BOTHELL, Wash. , Sept. 7, 2017   BioLife ... developer, manufacturer and marketer of proprietary clinical grade cell and ... media ("BioLife"), announces that Mike Rice , President and ... Rodman & Renshaw 19 th ... 3:25 p.m. Eastern time (12:25 p.m. Pacific time). The conference ...
(Date:9/6/2017)... 2017 Eli Lilly and Company (NYSE: ... data for galcanezumab and lasmiditan, two investigational treatments for ... Society (IHC) taking place Sept. 7-10 in ... new, long-term data from an open-label study evaluating the ... mg and 240 mg) for the prevention of migraine. ...
(Date:9/5/2017)... Oramed Pharmaceuticals Inc. (NASDAQ: ORMP ) (TASE: ... on the development of oral drug delivery systems, announced ... the U.S. Food and Drug Administration (FDA) regarding ORMD-0801, ... At the meeting, the FDA gave ... ORMD-0801, would be a Biologics License Application (BLA).  Such ...
Breaking Medicine Technology:
Cached News: